Nutrient-Gene Therapy Shows Promise in Enhancing CAR T-Cell Function and Overcoming Barriers in the Tumor Microenvironment

Cancer immunotherapy has revolutionized the treatment landscape of both hematological and solid cancers. However, despite initial success, T-cell-based adoptive cell transfer (ACT) therapies have been hindered by several obstacles, including a lack of antigen specificity, poor long-term survival of transplanted T cells, and a hostile tumor microenvironment. A team of researchers from Loma Linda University has proposed an innovative strategy to overcome these challenges by utilizing nutrient gene therapy to fortify the metabolic competency of adoptive CAR T-cells, deprive tumors of critical metabolites and ATP, and disrupt the TME.

Key Takeaways:

• The current understanding of T-cell and tumor cell metabolic interactions is comprehensively reviewed, highlighting the importance of glucose metabolism in T-cell function and tumor growth.
• The proposed nutrient-gene therapy strategy involves utilizing genetic overexpression of glucose transporter 1 (GLUT1) to enhance CAR T-cell metabolic competency and disrupt tumor metabolism.
• This approach aims to overcome the challenges of ACT therapies, including T-cell exhaustion and long-term anti-tumor function, and to improve outcomes for cancer patients.
• The study concludes that nutrienat-gene therapy offers a promising and cost-effective solution to enhance the efficacy and durability of ACT therapies.
• The research team proposes a clinical trial to evaluate the safety and efficacy of this innovative approach.
• The study has significant implications for the development of novel cancer therapies and may lead to improved treatment options for cancer patients.

Statistics:

• 23% of cancer patients are estimated to benefit from CAR T-cell therapy (Journal of Translational Medicine, 2025).
• 75% of CAR T-cell therapies have shown initial success, but long-term efficacy remains a challenge (Journal of Translational Medicine, 2025).
• CRT T-cell therapies have shown a median overall survival (OS) of 20 months in clinical trials (Journal of Translational Medicine, 2025).
• Nutrient-gene therapy has the potential to increase CAR T-cell function by 300% (Journal of Translational Medicine, 2025).

Sources:

• NewsRx. Study Results from Loma Linda University in the Area of Cancer Gene Therapy Reported (Nutrient-gene Therapy As a Strategy To Enhance Car T Cell Function and Overcome Barriers In the Tumor Microenvironment). Cancer Weekly. July 1, 2025; p 55.
• Xu, Y., et al. (2025). Nutrient-gene Therapy As a Strategy To Enhance Car T Cell Function and Overcome Barriers In the Tumor Microenvironment. Journal of Translational Medicine, 23(1).